Evidence map›Paper›PMID 28115953›Full record

ArticleJournal of contemporary brachytherapy2016

Comparative cost-effectiveness of focal and total salvage

Max Peters, Marjanne A Piena, Lotte M G Steuten, Jochem R N van der Voort van Zyp, Marinus A Moerland, Marco van Vulpen

Open access · goldAbstract read
In one paragraph

Article in Journal of contemporary brachytherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Clinical efficacy and prognostic factors of CT-guidedCancer imaging : the official publication of the International Cancer Imaging Society · 2020
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Max PetersDepartment of Radiation Oncology, University Medical Center Utrecht, The Netherlands; Both authors contributed equally to this research.
Marjanne A PienaUniversity of Twente, Enschede, The Netherlands; Both authors contributed equally to this research.
Lotte M G SteutenFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Jochem R N van der Voort van ZypDepartment of Radiation Oncology, University Medical Center Utrecht, The Netherlands.
Marinus A MoerlandDepartment of Radiation Oncology, University Medical Center Utrecht, The Netherlands.
Marco van VulpenDepartment of Radiation Oncology, University Medical Center Utrecht, The Netherlands.
University Medical Center Utrecht · NLFred Hutch Cancer Center · USUniversity of Twente · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFocal salvage (FS) iodine 125 ( MATERIAL AND

methodsA decision analytic Markov model was developed, which compares costs and QALYs associated with FS and TS. A 3-year time horizon was adopted with six month cycles, with a hospital perspective on costs. Probabilities for genitourinary (GU) and gastrointestinal (GI) toxicity and their impact on health-related quality of life (SF-36) were derived from clinical studies in the University Medical Center Utrecht (UMCU). Probabilistic sensitivity analysis, using 10,000 Monte Carlo simulations, was performed to quantify the joint decision uncertainty up to the recommended maximum willingness-to-pay threshold of €80,000/QALY.

resultsFocal salvage dominates TS as it results in less severe toxicity and lower treatment costs. Decision uncertainty is small, with a 97-100% probability for FS to be cost-effective compared to TS (€0-€80,000/QALY). Half of the difference in costs between FS and TS was explained by higher treatment costs of TS, the other half by higher incidence of severe toxicity. One-way sensitivity analyses show that model outcomes are most sensitive to utilities and probabilities for severe toxicity.

conclusionsFocal salvage

Indexed as

125Ibrachytherapycost-effectivenessfocal salvageprostate cancerwhole-gland salvage

Identifiers

PMID28115953
PMCPMC5241382
OpenAlexW2583882346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.